HOME >> BIOLOGY >> NEWS
Are we mice or men? Gene mutation linked to improving heart failure in mice proves lethal in humans

The goal of molecular medicine is to utilize the wealth of available experimental tools to develop treatments for human disease. Researchers develop animal models of a disease, investigate the underlying biological mechanisms, and conceive and test novel therapies until a successful treatment is found. The treatment strategy is then developed for human trial.

However, what if the outcome of the treatment was profoundly different in humans when compared with mice? Are we failing to consider the critical differences between mouse and man? Two studies published in the March 14 issue of the Journal of Clinical Investigation led by Evangelia Kranias and researchers at the University of Cincinnati reveal that a mutation in the human gene encoding the protein phospholamban (PLN) is linked to heart failure. In striking contrast to previous reports that indicate that "knock-out" or inhibition of PLN is beneficial in mouse models of heart failure, the researchers reveal that humans with mutated forms of PLN develop lethal heart failure.

Heart failure is a leading cause of human morbidity and mortality worldwide and costs close to $18 billion in health-carerelated costs in America each year. Characterized by suppressed calcium cycling in the heart, it impairs the ability of the heart to supply adequate oxygen- and nutrient-rich blood to the body. Calcium regulates the contraction and relaxation of heart muscle and PLN acts to halt calcium cycling at the end of the contraction so that muscles may relax between beats.

Recent experimental successes in mice have generated much enthusiasm for treating an array of conditions that ultimately result in heart failure by "knocking-out" the PLN gene and thereby enhancing calcium cycling.

However, the effect of inhibiting PLN in cases of cardiac hypertrophy (which can progress to heart failure) was unknown.

In the first study, the researchers studied two mouse models of c
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
10-Mar-2003


Page: 1 2 3

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. How an insidious mutation fools DNA replication
4. Using statistics to decipher secrets of natural mutation
5. Rare mutations can significantly increase risk factor for heart disease
6. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
7. LBP-1a gene mutation linked to disruption of normal fetal development
8. Genetic mutation found that is major contributor to type 1 diabetes
9. The mother lode of mutations
10. Gene mutation causes progressive changes to cell structure in children with Progeria
11. Single gene mutation muddying Parkinsons risk forecasts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Research and Markets ... has announced the addition of the "Implantable Biomaterials ... report to their offering. Report Highlights: ... detailed analysis on current and future market trends to identify the investment ... as the base numbers Key market trends across the ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics ... its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing ... existing policy. AMIA recommended that NIH earmark funding for researchers to produce and ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita ... full spectrum of drug and device development, and Prism Clinical Research , ... clinicians, today announced Verified Clinical Trials (VCT) has been selected by ...
Breaking Biology Technology:
Cached News: